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A multifunctional poly(curcumin) nanomedicine
for dual-modal targeted delivery, intracellular
responsive release, dual-drug treatment and
imaging of multidrug resistant cancer cells†
Jining Wang,‡a Feihu Wang,‡a Fangzhou Li,a Wenjun Zhang,a Yuanyuan Shen,*a
Dejian Zhou*b and Shengrong Guo*a
A multifunctional anti-cancer nanomedicine based on a biotin–poly(ethylene glycol)–poly(curcumin-dithio
dipropionic acid) (Biotin–PEG–PCDA) polymeric nanocarrier loaded with paclitaxel (PTX), magnetic nano-
particles (MNPs) and quantum dots (QDs) is developed. It combines advantageous properties of efficient
targeted delivery and uptake (via biotin and MNP), intracellular responsive release (via cleavable PCDA
polymer), fluorescence imaging (via QD) and combined PTX-curcumin dual-drug treatment, allowing for
overcoming drug resistance mechanisms of model multidrug resistant breast cancer cells (MCF-7/ADR).
The PTX/MNPs/QDs@Biotin–PEG–PCDA nanoparticles are highly stable under physiological conditions,
but are quickly disassembled to release their drug load in the presence of 10 mM glutathione (GSH). The
nanoparticles show high uptake by tumour cells from a combined effect of magnet targeting and biotin
receptor-mediated internalization. Moreover, curcumin, an intracellularly cleaved product of PCDA, can
effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to
increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and
therapeutic efficacy against MCF-7/ADR cells. Taken together, this novel tumour-targeting and traceable
multifunctional nanomedicine is highly effective against model MDR cancer at the cellular level.
1. Introduction
Multi-drug resistance (MDR) is a common but one of the greatest
challenges currently faced in cancer treatments where cancer cells
are resistant to a variety of structurally and mechanistically
unrelated chemotherapeutic agents.1 MDR tumour cells can
eﬀectively remove drugs from their cellular interior to prevent
drug accumulation, reducing the sensitivity of tumor cells to
therapeutic drugs.2 MDR can be caused by both biochemical
and physical obstructions such as the over-expression of eﬄux
pumps (P-glycoprotein, P-gp), upregulated pathways (NF-kB and
PI3K), reduced penetration of drugs into the cells, and so on.3,4
An attractive strategy to overcomeMDR cancer is to co-administer
a specific eﬄux pump inhibitor along with the cancer chemo-
therapy drug to increase the drug accumulation and improve
treatment eﬃcacy.5 Curcumin, a natural diphenol compound
extracted from the ground rhizomes of Curcuma longa, has shown
attractive and selective cytotoxicity towards cancer cells over healthy
cells with broad antitumor properties.6 More importantly, curcumin
is able to independently down-regulate both the PI3K/Akt and NF-kB
pathways and suppress the P-gp expression.7,8 Therefore, curcumin
can be used as an eﬀective sensitizer forMDR cancer cells to increase
their therapeutic response to conventional chemotherapeutic agents.
However, the extremely low solubility and poor stability of curcumin
under physiological conditions have greatly limited its bioavailability
and therapeutic eﬃcacy. To overcome this issue, herein we have
directly incorporated curcumin into a disulfide-linked hydrophobic
backbone of a PEGylated amphiphilic diblock copolymer (biotin
poly(ethylene glycol)–poly(curcumin-dithio dipropionic acid)) to
improve its stability and water-solubility. Moreover, we have grafted
biotin at the hydrophilic end of the copolymer as an active cancer
targeting ligand because biotin binds strongly to the biotin receptors
which are widely over-expressed on cancer cell surfaces.9,10 Impor-
tantly, the resulting amphiphilic copolymer (hereafter abbreviated
as Biotin–PEG–PCDA, see Scheme 1) can self-assemble into a stable
core/shell nanoparticle (NP) in an aqueous environment, acting as
an efficient nanocarrier for other cancer chemo-therapeutic drugs
(e.g. paclitaxel, PTX). As a result, both the chemotherapeutic agent
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(PTX) and the chemosensitizer can be efficiently delivered into the
target cancer cell at the same time.11 Importantly, the disulfide
linkage at the PCDA hydrophobic section can be readily cleaved by
the high intra-cellular glutathione (GSH) content, leading to the
co-release of curcumin and PTX intracellularly. The released
curcumin can down-regulate the P-gp expression, increasing
intracellular PTX accumulation and enhancing its cytotoxicity
against the model MDR cancer (MCF-7/ADR) cell lines.12,13
Meanwhile, the ability to deliver high drug dose to the target
tumour cells can specifically greatly reduce the harmful side eﬀects
of most chemotherapeutic reagents.14–16 To achieve this ability, we
have further loaded Fe3O4 magnetic particles into the hydrophobic
core of the Biotin–PEG–PCDA nanoparticles (NPs), allowing for
magnetic field guided delivery of the multifunctional anticancer
nanomedicine to target cancer cells with greatly improved efficiency.
To further improve the multifunctionality of the nanomedicine,
we have encapsulated a non-toxic, Cd2+-free CuInS2/ZnS core/
shell quantum dot (QD) into the hydrophobic core to enable it
for traceable delivery. An advantage of using QDs over other
fluorescent dyes for traceable delivery is their bright, stable
and size-tuneable fluorescence, allowing for sensitive, long-term
monitoring and tracking.17,18
2. Experimental
2.1 Materials
A biotin–poly(ethylene glycol)–poly(curcumin-dithiodipropionic
acid) copolymer (Biotin–PEG–PCDA, the molecular weights of
PCDA and Biotin–PEG–PCDA are 6990 and 10750, respectively) was
synthesized as described previously.19,20 Hydrophobic CuInS2/ZnS
quantum dots (QDs) capped with dodecanethiol ligands were
purchased from PlasmaChem (German). Paclitaxel was obtained
fromZiyunBiotechnology Co., Ltd, (Yunnan, China). 3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) and dimethyl
sulfoxide (DMSO) were purchased from Sigma Co. Ltd (USA).
Penicillin–streptomycin, RPMI-1640medium (R1145), fetal bovine
serum (FBS), and 0.25% (w/v) trypsin–0.03% (w/v) EDTA solution
were purchased from Gibco BRL (Gaithersburg, MD, USA). All
other reagents were at least analytical grade and used without
further purification.
Breast cancer cell lines MCF-7 and MCF-7/ADR (multidrug
resistance) were kindly donated by the Department of Pharma-
cology, Chinese Academy of Sciences, Shanghai. The cells were
cultured in 75 cm3 flasks in a humidified atmosphere with
5% CO2 at 37 1C in RPMI-1640 medium supplemented with
10% fetal bovine medium (FBS) and 100 U mL1 penicillin and
100 mg mL1 streptomycin. Cells grown to confluence were sub-
cultured every other day after trypsinized with 0.25% trypsin–
EDTA and diluted (1/3) in fresh growth medium.21
2.2 Preparation of magnetic nanoparticles
Fe3O4 MNPs were prepared by using the co-precipitation method
as described previously.22 Briefly, FeCl36H2O and FeCl24H2O
(2 : 1 molar ratio) were dissolved in de-oxygenated pure water,
into which NH3H2O was then added dropwise under vigorous
stirring and heated to 80 1C to yield Fe3O4 MNPs. Then oleic acid
Scheme 1 (A) Construction of the PTX/MNPs/QDs@Biotin–PEG–PCDA hybrid multifunctional nanoparticles. (B) The disulphide linkage of the hydrophobic
PCDA core can be quickly cleaved by the high GSH content intracellularly, simultaneously releasing its curcumin and PTX payloads. (C) The incorporated
magnetic nanoparticles (MNPs) into the multifunctional NP allow for magnetic field guided concentration of the NPs on target cells for increased uptake while
the encapsulated QDs allow for sensitive fluorescence detection and tracking. (D) TheNP surface biotin groups allow for efficient uptake via cancer cell surface
over-expressed biotin receptors and subsequently lead to GSH-triggered co-release of curcumin and PTX payloads. Curcumin can down regulate the
expression of P-glycoprotein (P-gp) to improve PTX intracellular accumulation and to enhance its cytotoxicity to model MDR cancer (MCF-7/ADR) cells.
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(B10% of the mass of MNPs) was added to cap the MNPs
rendering them hydrophobic. The resulting Fe3O4@QA were
washed repeatedly by ethanol and isolated by using a permanent
magnet. The size and morphology of the MNPs was measured
by transmission electron microscopy (TEM) on a JEM-2100F
TEM (JEOL, Japan). Their IR spectra were recorded using a
Bruker EQUINOX 55 Fourier transformed infrared spectrophoto-
meter (FT-IR, Germany) to detect the surface coating functional
groups.
2.3 Preparation of PTX-loading PTX/MNPs/QDs@BPP NPs
The PTX-loaded nanoparticles were prepared using the O/W
emulsion solvent evaporation method following our previously
established procedures. Briefly, a mixture of 10 mg MNPs, 5 mg
QDs, 2 mg PTX and 20 mg Biotin–PEG–PCDA was co-dissolved
in dichloromethane to form a uniform solution, which was
then slowly poured into deionized water under sonication to
form an oil-in-water emulsion. After stirring at room tempera-
ture for six hours, the organic solvent was rotary evaporated at
40 1C under reduced pressure to obtain a suspension, which was
then centrifuged at 3000 rpm for 20 min to remove aggregated
particles and un-encapsulated free PTX. The resulting clear
supernatant was lyophilized to obtain the multifunctional PTX/
MNPs/QDs@BPP nanoparticles.
2.4 Evaluation of particle size and zeta potential
The morphology of PTX/MNPs/QDs@BPP NPs was observed
using a transmission electron microscope (TEM, JEM-2100F,
JEOL, Japan). A drop of the diluted NP solution was placed
on a copper grid, stained with 2% phosphotungstic acid and
dried before measurement. The average hydrodynamic size and
distribution were measured on a Zetasizer Nano ZS (Malvern
Instruments Ltd, UK). Zeta potentials of nanoparticles were
measured on Zetasizer Nano ZS/ZEN3600 (Malvern Instruments,
Herren-berg, Germany) at 25 1C. Each sample was tested in
triplicate.
2.5 Evaluation of particle rehydration and dilution stability
To investigate the particle rehydration and stability upon dilution
which is crucial for eﬃcient drug carriers, the lyophilized powder
was redispersed in deionized water by sonication at a concentration
of 1mgmL1. The average hydrodynamic size and the polydispersity
index of the nanoparticle were tested repeatedly to check whether
agglomeration occurred during this process. The resulting solution
was then diluted by pure water to investigate whether the NPs
were stable upon dilution.
2.6 Investigation of particle magnetic and fluorescent
properties
The PTX/MNPs/QDs@BPP NPs were dispersed in an aqueous
solution at a concentration of 1 mg mL1, then a permanent
magnet was used to determine their magnetic response. Magnetic
NPs were able to be pulled to the side wall by an external magnetic
field, but were redispersed quickly and uniformly after themagnet
was removed. The fluorescence absorption and emission spectra
of the NPs were recorded on a HATACHI F-7000 fluorescence
spectrophotometer (Japan) to confirm the loading of the QDs.
2.7 Determination of drug-loading parameters
1 mg of the PTX/MNPs/QDs@BPP NPs was dissolved in 2 mL of
50% acetonitrile in water being followed by sonication for
10 min to completely break the assembly. The solution was
centrifuged at 10 000 rpm for 10 min and the supernatant
was filtered with a 0.2 mm syringe filter. The resulting PTX
concentration was analysed by high-performance liquid
chromatography (HPLC) equipped with a LC 10ADvp pump
and a SPD-10Avp UV-vis detector (Waters, USA). The sample
solution was injected at least three times at a volume of 20 mL
into a Dikma-ODS C18 column (150 mm  4.60 mm, 5 mm)
preceded by a C18 guard column (Dikma, China). The mobile
phase was 50% acetonitrile in water with an elution rate of
1.0 mLmin1. Paclitaxel detection wavelength was set at 227 nm.
The drug concentration of PTX was estimated against a standard
calibration curve established under identical conditions. The
drug-loading eﬃciency (DL) and encapsulation eﬃciency (EE)
were calculated by the following equations:
DL% ¼ weight of the PTX in nanoparticles
weight of the nanoparticles dissolved
 100%
EE% ¼ weight of the PTX in nanoparticles
weight of the feeding PTX
 100%
2.8 In vitro drug release study
The nanoparticle solution was transferred into a dialysis tube
(molecular weight cut oﬀ = 3500 Da, Snakeskin, Pierce, USA)
and suspended in phosphate buﬀer saline (PBS, 0.15 M NaCl,
pH 7.4) containing 1% Tween 80 to imitate a physiological
environment. PBS solutions containing 10 mM and 10 mM
glutathione were used to mimic the blood and intracellular
environment. The release experiments were carried out in an
incubator (SHA-C, China) under gentle stirring (100 rpm) at
37 1C. At predetermined time intervals, the release medium was
withdrawn and replaced with an equal volume of fresh release
medium. The collected samples were analyzed byHPLC as described
above to determine the amount of released PTX. Meanwhile
PTX release from stock solution was used as control.
2.9 In vitro fluorescence imaging and cellular uptake study
MCF-7/ADR cells in a logarithmic growth period were seeded
at a density of 2  105 cells per well in a 6-well plate and
incubated overnight. After removing the culture medium, 2 mL
of the fresh medium containing the PTX/QDs@PEG–PCDA,
PTX/QDs@BPP or PTX/MNPs/QDs@BPP (all containing the
same amounts of QDs) were added to each well. The cells were
also scheduled to be treated with or without an external
magnet. After 4 h incubation, the cells were washed three times
with cold PBS to remove unbound NPs, and then imaged on an
Olympus IX51 fluorescence microscope (Olympus, Tokyo,
Japan) where both fluorescence and bright field photographs
were recorded.
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For cellular uptake studies, the cells were treated with diﬀerent
NP formulations, PTX/QDs@PEG–PCDA, PTX/QDs@BPP, PTX/
MNPs/QDs@BPP, PTX/QDs@BPP plus magnetic field and
PTX/MNPs/QDs@BPP plus magnetic field, respectively. At pre-
designated time points (2, 4 and 8 h), the cells were washed
three times with ice-cold PBS, then collected by centrifugation
and then re-suspended in 0.5 mL PBS. The mean fluorescent
intensity of the cells was measured on a BD LSRFortessa flow
cytometer (Becton Dickinson, America).
2.10 In vitro cytotoxicity assay
The cytotoxicities of the diﬀerent NPs were determined by the
MTT assay. Briefly, MCF-7/ADR cells in their logarithmic
growth were seeded in 96-well plates at a seeding density of
6000 cells per well. Following attachment overnight, the culture
medium was carefully replaced with 150 mL of medium containing
serial dilutions of the diﬀerent drug/NP formulations: free-PTX
solution (PTX), free PTX + curcumin physical mixture, PTX@
PEG–PCDA, PTX@BPP, PTX/MNPs/QDs@BPP and PTX/MNPs/
QDs@BPP plus magnetic field. The concentrations of PTX used
in the treatment ranged from 0.1 to 100 mg mL1. After
incubation for 48 h,15 mL of the MTT solution (5 mg mL1 in
PBS) was added to each well. The plates were incubated for an
additional 4 h at 37 1C and then the medium was removed.
Thereafter, 150 mL of DMSO was added to each well to dissolve
the formazan crystals formed. The absorbance of each well was
recorded on a Bio-Rad 680 microplate reader (Bio-Rad Labora-
tories, Hercules, CA) at a set wavelength of 570 nm.
All the cell based experiments were done in triplicate with six
parallel samples. Cells treated with culture medium containing
0.1% DMSO were used as control. The cytotoxicity of the drug-
loaded NPs was expressed as an IC50 value defined as the drug
concentration required to inhibit cell growth by 50% relative to
the control. These values were calculated by nonlinear regression
analysis of the response curves. The cell growth inhibition rate
and the reversing drug resistance index onMCF-7/ADR cells were
calculated as follows:
Inhibitory rate ¼ ðA570 control A570 sampleÞ
A570 control
 100%
Resistance reversal index ðRRIÞ ¼ IC50 free PTX
IC50 sample
3. Results and discussion
Our approach to the multifunctional anticancer nanomedicine
is shown schematically in Scheme 1. An amphiphilic biotin
modified poly(ethylene glycol) poly(curcumin-dithiodipropionic
acid) (Biotin–PEG–PCDA) diblock copolymer was prepared. It
was subsequently assembled into stable core–shell NPs in the
presence of hydrophobic PTX, Fe3O4 MNPs and QDs, during
which the hydrophobic drugs, MNPs and QDs are encapsulated
within the hydrophobic core, forming PTX/MNPs/QDs@Biotin–
PEG–PCDA hybrid nanoparticles (abbreviated as PTX/MNPs/
QDs@BPP). The encapsulation of the hydrophobic entities
significantly increases the nanoparticle stability and structural
integrity under physiological conditions via enhanced hydro-
phobic interactions. Moreover, each species brings in a unique
function to the multifunctional nanomedicine: QDs for sensitive
fluorescence tracing, MNPs for magnetic targeting, PTX for
providing chemotherapy, biotin for active cancer cell targeting,
PEG for improving water-solubility, stability and resisting non-
specific adsorption, PCDA for curcumin incorporation and GSH-
triggered intracellular release. Together, all these functional
entities allow us to build a novel, multifunctional nanomedicine
platform for traceable, targeted delivery, efficient GSH-triggered
intracellular drug release and combinational dual-drug therapy
for overcoming MDR cancer at the cellular level.
3.1 Characterization of PTX/MNPs/QDs@BPP nanoparticles
Fig. 1A shows the TEM image of oleic acid coated Fe3O4 MNPs
used in this study. They mostly appear in a spherical shape
with an average MNP core diameter of B10 nm. Fig. 1B shows
the FT-IR spectrum of the MNPs. During MNP preparation by
co-precipitation, the MNP surfaces were readily covered with
hydroxyl groups in an aqueous environment. The strong absorption
bands at 1628 and 3430 cm1 were assigned to the O–H bending
and stretching vibration modes respectively.23 Compared with bare
Fe3O4, new absorption bands at 2924 and 2855 cm
1 were observed
for the oleic acid capped MNPs which were attributed to the
existing –CH2 asymmetric and symmetric stretching of oleic acid,
Fig. 1 (A) A representative TEM image of Fe3O4@OA; (B) the FTIR spectra
of the bare Fe3O4 (red) and Fe3O4@OA (black line).
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respectively. The band at 1456 cm1 was attributed to COO and
the band at 586 cm1 was corresponded to Fe–O.22 These data
indicated that the Fe3O4 NPs were successfully coated with oleic
acid ligands via their COO groups, leaving the alkyl chains
exposed to render them hydrophobic. This was essential for
loading them into the hydrophobic cavity of the self-assembled
amphiphilic Biotin–PEG–PCDA copolymer NPs.
The preparation procedures of PTX/MNPs/QDs@BPP multi-
functional NPs are shown schematically in Fig. 2. Biotin–PEG–
PCDA was used to load MNPs, QDs and PTX by the simple O/W
emulsion and solvent evaporation method. The success of the
multifunctional NP assembly was confirmed by TEM imaging
(Fig. 3A): smooth spherical NPs with uniform sizes were clearly
observed. The sizes of the NPs were found to be in the range of
B100 nm, which was smaller than those found by the dynamic
light scattering (DLS) shown in Fig. 3B. This is reasonable
because TEM image was collected in dehydrated state, where
the sizes were mostly corresponded to their inorganic cores and
the organic shell was mostly invisible. The zeta potential of the
particles was found to be 11.36 mV, consistent with NPs
capped with neutral hydrophilic PEGs. Because most of the
blood components are negatively charged, the negative zeta
potential together with surface PEGs of the NPs should increase
their stability by electrostatic repulsion, reducing the chances
of particle agglomeration.
The magnetic and optical properties of the NPs were further
investigated to examine whether the MNPs and QDs were properly
assembled. As shown in Fig. 3C, the NP solution exhibited a yellow
colour uniformly, suggesting that they were fully dissolved without
aggregation or precipitation. The NPs were rapidly concentrated
toward the side wall of the cuvette upon applying an external
magnet field, where the solution colour became much less strong,
indicating that the MNPs have indeed been successfully encapsu-
lated into the NPs. Therefore, it is possible to guide the NPs by
using an external magnetic field. Upon removal of the magnetic
fields, the NPs were rapidly re-dispersed into a uniform solution,
indicating no agglomeration of the NPs. Fig. 3D showed that the
maximum fluorescence emission wavelength of the free QDs and
the multifunctional NPs containing the same amount of QDs
were almost identical, peaking at 705 and 706 nm, respectively.
All these indicated that the QDs were successfully loaded into the
NPs, allowing them to be readily detected via the strong fluores-
cence of the encapsulated QDs.24
3.2 Evaluation of particle rehydration and dilution stability
At first, granules existed when the lyophilized hybrid NP powder
was re-dispersed in deionized water. However, the solution became
completely clear and uniform after a brief sonication. The average
hydrodynamic diameters of the NPs were found to be B170 nm
with a unimodal size distribution (PDI = 0.25), consistent to those
measured by the TEM. The re-dispersed NP powder solution thus
showed no significant diﬀerence to as-prepared NPs, suggesting
that the multifunctional NPs can be conveniently lyophilized and
then readily rehydrated and redispersed in water. This indicated
that the NPs could be readily lyophilized for convenient long term
storage without aﬀecting their structural integrity, a very beneficial
property for nanomedicine. To further investigate their stability
against dilution, the stock solution (1 mg mL1) was diluted by
pure water to give diﬀerent concentrations, and then the resulting
hydrodynamic sizes were measured. As shown in Table 1, the NPs
at diﬀerent concentrations exhibited almost identical particle sizes
with a narrow size distribution even at a concentration of as low
as 1 mg mL1. Moreover, they also gave very similar negative
zeta potentials of about 10 mV. These results indicated that
the NPs developed herein possessed excellent stability against
dilution and could retain their nanoscale structural integrity
even at very low concentrations. Obviously, these results also
demonstrated that there was no leaching of the encapsulated
Fig. 2 Schematic procedures of synthesising Biotin–PEG–PCDA and the
assembly of PTX/MNPs/QDs@BPP. Fig. 3 The physicochemical characteristics of PTX/MNPs/QDs@BPP NPs.
(A) A typical TEM image of PTX/MNPs/QDs@BPP NPs; (B) histograms showing
the size distribution of PTX/MNPs/QDs@BPP NP; (C) photograph of an
aqueous solution of PTX/MNPs/QDs@BPP NP showing a uniform yellow
colour without any visible aggregation (a), the NPs were rapidly gathered
at the side wall of the cuvette by an external magnet (b), the NPs were
re-dispersed into a uniform solution after the magnet was removed (c); (D) the
fluorescence emission spectra of the free QDs and PTX/MNPs/QDs@BPP.
Journal of Materials Chemistry B Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
A
pr
il 
20
16
. D
ow
nl
oa
de
d 
on
 2
5/
05
/2
01
6 
14
:4
7:
56
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2016 J. Mater. Chem. B, 2016, 4, 2954--2962 | 2959
quantum dots and magnetic nanoparticles from the nano-
medicine, otherwise a range of diﬀerent sized particles would
be observed. Such properties would be extremely beneficial for
in vivo applications, allowing for the eﬀective minimization
of any unwanted premature drug release and degradation and
hence reducing side-eﬀects. The outstanding stability of the
NPs obtained here is attributed to the strong hydrophobic
interactions among the PCDA backbone, hydrophobic PTX
molecules, MNPs and QDs at the NP core together with the
exposed hydrophilic PEG moieties.
3.3 Paclitaxel-loading parameters
The O/W emulsion solvent evaporation method appeared to
be particularly suitable for the incorporation of PTX into self-
assembled Biotin–PEG–PCDA NPs. The PTX-loading weight effi-
ciency (DL) and encapsulation efficiency (EE) of PTX/MNPs/
QDs@Biotin–PEG–PCDA were determined as 10.3% and 80.7%,
respectively. Such high PTX weight loading and encapsulation
values were ascribed to the presence of sufficiently large and
stable hydrophobic cores of the Biotin–PEG–PCDA copolymer NPs
which were further stabilised by hydrophobic interactions with
the MNPS and QDs, allowing for the efficient encapsulation of
highly hydrophobic paclitaxel molecules.
3.4 In vitro drug release studies
In this study, pH 7.4 phosphate buﬀer solution without and with
10 mM or 10 mM glutathione were selected to imitate physio-
logical, blood and intracellular environments, respectively. The
release medium also contained 1% w/v Tween 80 as good sink
conditions. In addition, prior to conducting release assays, PTX
release from stock solution was investigated as a control. It was
found that about 80% of non-encapsulated PTXs were released
in approximately 5 h, suggesting that free drugs could freely
diﬀuse through the dialysis membrane. Fig. 4 represents the
cumulated in vitro release profiles of PTX from the multifunc-
tional NPs in diﬀerent release medium. In contrast to the rapid
release observed from PTX stock solution, a pronounced time
prolongation of PTX release from the NPs was evident. For
example, only about 25% of the PTX load was released from
the NPs in pH 7.4 PBS after 80 h. Importantly, the cumulative
PTX release profile showed a strong glutathione dependence:
PTX was released much more quickly when exposed to PBS
containing 10 mM glutathione, where B65% and 90% of drug
loads were released at 12 and 48 h, respectively. In contrast, only
B25% and 30% of drug loads were released with 10 mM
glutathione at the same time point. This is mainly due to the
eﬀective cleavage of disulfide linkage of the hydrophobic PCDA
backbone by GSH, allowing for rapid degradation of the hydro-
phobic NP core and the release of loaded drugs.25 Therefore,
the PTX/MNPs/QDs@BPP NPs should be stable under normal
physiological or blood circulation conditions (with low GSH
content), but could readily release their drug load once entered
into the target cancer cells/tissues triggered by the high intra-
cellular GSH content (1–10 mM).
3.5 Cell targeting and cellular uptake studies
The encapsulation of strongly fluorescent Cd2+-free CuInS2/ZnSQDs
into the NPs allowed for convenient monitoring of the carrier cell
uptake via the encoded QD fluorescence by fluorescence micro-
scopy. As shown in Fig. 5A, when the PTX/QDs@PEG–PCDA
(without biotin) was incubated with the MCF-7/ADRcells for 4 h,
the cells showed minimal QD fluorescence, suggesting minimal
cell uptake. The introduction of biotin to the carrier (PTX/
QDs@Biotin–PEG–PCDA) was found to improve the cell uptake
significantly as evidenced by a strong QD fluorescence (Fig. 5B).
This result confirmed that the biotin could act as a targeting ligand
to increase cell uptake of the NPs. As shown in Fig. 5C, applying a
magnetic field to the PTX/QDs@Biotin–PEG–PCDA (without MNP
encapsulation) incubation system appeared to have no effect on
the fluorescence intensity of treated cells. However, applying a
magnetic field to help pull down the multifunctional NPs from top
of the incubation solution was found to significantly increase the
fluorescent intensity of the PTX/MNPs/QDs@BPP (containing
MNPs) treated cells, where almost every cell was found to display
a strong fluorescence (Fig. 5E). The fluorescence intensity was also
stronger than that shown in Fig. 5D without applying magnetic
field, suggesting that the use of magnetic field for targeted concen-
tration of the NPs is effective in increasing the cell uptake. Taken
together, these results revealed that the combination of magnetic
and biotin targeting could significantly improve the cell uptake
efficiency of the PTX/MNPs/QDs@BPP NPs, demonstrating that the
amount of QDs and MNPs encapsulated within the nanomedicine
are enough to make them useful for simultaneous fluorescence
imaging and magnetic targeting.
Table 1 Particle size and zeta potential of PTX/MNPs/QDs@BPP NPs at
diﬀerent concentrations
Concentration
(mg mL1) Size (nm) PDI
Zeta-potential
value
100 181.1  3.7 0.15  0.04 12.2  1.8
10 186.5  2.6 0.21  0.06 11.1  0.9
1 188.7  2.0 0.22  0.01 9.6  1.4
Fig. 4 Typical in vitro release profiles of paclitaxel from NPs under
diﬀerent simulated conditions at 37  0.5 1C.
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To further investigate the magnetic field and biotin medi-
cated cell-targeting eﬀects, the mean fluorescent intensity
(MFI) of MCF-7/ADR cells after incubation with diﬀerent NP
formulations for 2, 4, and 8 h was quantified by flow cytometry.
As shown in Fig. 6, the MFI of cells was found to increase with
the increasing incubation time, consistent with more cell
uptake of the NPs with time. Moreover, all of the biotinylated NPs
(PTX/QDs@BPP; PTX/MNPs/QDs@BPP) showed higher MFIs than
their non-biotinylated NP counterpart (PTX/QDs@PEG–PCDA).
This result was consistent with that observed in the fluorescence
microscopy imaging experiment described above, confirming
that biotin modification on the NP surface can improve cell
uptake presumably via efficient binding to over-expressed
biotin receptors on MCF-7/ADR cell surfaces. Moreover, cells
treated with the PTX/QDs@BPP (containing no MNPs) showed
no measurable difference in the cellular MFIs in the presence
or absence of external magnetic field, confirming that the
application of external magnetic field alone did not impact
the cell uptake of the NPs. However, a significantly higher MFI
(by B87% at 8 h) was observed for cells incubated with PTX/
MNPs/QDs@BPP (containing MNPs) in the presence of an
external magnetic field than that in the absence of external
magnetic field, presumably via magnetic field guided concen-
tration of the NPs next to the cells. These results indicated that
the MNP containing multifunctional NPs were more efficiently
taken up by tumour cells from the combined effects of magnet
field and biotin dual-modal targeting.
3.6 Cytotoxicity assay in MCF-7/MDR cells
Loading of chemotherapeutic drugs into polymeric NPs could
increase their cytotoxicity to target cells over free drug.24,26 Here
the cytotoxicity and drug resistant reversal eﬃcacy of the diﬀerent
formulations of the PTX-loaded multifunctional NPs against the
MDR cancer (MCF-7/ADR) cells were evaluated by the standard
MTT based cytotoxicity assays. Our previous work showed that
the MCF-7/ADR cells were highly resistant to free PTX treatment
compared to the PTX-sensitive MCF-7 cell line, displaying a high
resistance index of 248. The results shown in Fig. 7 also con-
firmed the high resistance of MCF-7/ADR cells toward free PTX
treatment, giving a high IC50 value of 14.9 mg mL
1. The combined
application of free PTX and curcumin physical mixture reduced the
IC50 to 9.4 mg mL
1. Encapsulation of PTX into the PEG–PCDA NP
(e.g. PTX@PEG–PCDA) further reduced the IC50 to 7.1 mg mL
1,
Fig. 5 Fluorescent images of MCF-7/ADR cells after incubation with PTX/
QDs@PEG–PCDA (A), PTX/QDs@BPP (B), PTX/QDs@BPP plus an external
magnetic field (C), PTX/MNPs/QDs@BPP (D), and PTX/QDs@BPP plus an
external magnetic field (E).
Fig. 6 The mean fluorescent intensity of the MCF-7/ADR cells after
treatment with diﬀerent NP formulations with and without applied mag-
netic field for 2, 4, and 8 h. Data are expressed as the mean  S.D. (n = 3).
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suggesting increased cytotoxicity of PTX against the MCF-7/ADR
cells. The high resistance of theMCF-7/ADR cells towards free PTX
treatment is most likely due to their surface over-expressed
P-glycoprotein efflux pumps that can efficiently efflux out of the
internalised PTX molecules from the cellular interior, reducing
the intracellular PTX concentration and compromising the treat-
ment efficacy. When the MDR cells were treated with PTX-
containing PTX@PEG–PCDA NPs, the cleavage of the disulphide
linkage of the PCDA backbone triggered by the high intracellular
GSH content simultaneously released the curcumin (a degrada-
tion product of PCDA) and PTX payloads. Curcumin could then
effectively down regulate the expression of the efflux transporters
such as P-glycoprotein (P-gp), allowing for increased intracellular
PTX accumulation, and thereby enhancing the PTX based
chemotherapeutic treatment efficacy.
The combined eﬀect of combinational PTX and curcumin
treatment over PTX alone was also evident from the free PTX +
curcumin mixture (IC50: 9.4 vs. 14.9 mg mL
1). The diﬀerent
IC50 values between the free PTX + curcumin mixture and
PTX@PEG–PCDA perhaps originating from the latter can provide
the simultaneous intracellular release of PTX and curcumin,
maximising the combinational therapy efficacy.27 Moreover, the
biotin grafted PTX@BPP NP exhibited superior cytotoxicity as
compared to the biotin free PTX@PEG–PCDA NPs (IC50: 1.68 vs.
7.1 mg mL1). This revealed that biotin played a critical role in
enhancing cytotoxicity of the NPs, presumably by binding to
MCF-7/ADR cell surface over-expressed biotin receptors,28 leading
to increased cell uptake via receptor mediated endocytosis. This
result was also consistent with the flow cytometry measurement
results, where the biotin-grafted NPs showed higher cell uptake
than those without biotin. More importantly, the PTX/MNPs/
QDs@BPP multifunctional NPs were the most cytotoxic against
theMCF-7/ADR cells in the presence of an external magnetic field
among all of the treatment groups. Its IC50 value was consider-
ably lower (0.89 vs. 1.70 mg mL1) than that in the absence of
magnetic field, which again was fully consistent with the much
higher cell uptake observed from flow cytometry above. This
result clearly demonstrates that the combined magnetic field and
biotin dual-targeting strategy was more effective than those
relying on biotin targeting alone, a considerable advantage of
the multifunctional NPs reported herein over other traditional
single-modal targeting NPs.29
Table 2 summarised the ability of the above NP formulations to
reverse the drug resistance on MCF-7/ADR cells. This was given as
the resistance reversion index (RRI), which was defined as the ratio
of IC50 of free PTX to that of the PTX nanomedicine formulations.
As shown in Table 2, treatment with the PTX/MNPs/QDs@BPP in
the presence of external magnetic field had a RRI of 16.7 which
was significantly higher than any other treatments toward the
PTX-resistantMCF-7/ADR cells. This highly encouraging result
was benefited by the ability of the multifunctional NP to
eﬀectively exploit the magnetic/biotin dual-modal targeting to
achieve high cell uptake, eﬃcient intracellular GSH-triggered
co-release of curcumin and PTX for simultaneous dual-drug
therapy, and thereby maximising the treatment synergy to
overcome drug resistance in the MDR tumour cells. Therefore,
the PTX/MNPs/QDs@BPP NP developed herein appears to be a
highly eﬀective, targeted, and traceable multifunctional nano-
medicine for the eﬀective treatment of MDR cancer at the
cellular levels.
4. Conclusion
A novel magnetic/biotin dual-modal targeting and traceable
multifunctional nanomedicine (PTX/MNPs/QDs@BPP) for the
eﬃcient treatment of multi-drug resistance breast cancer at the
cellular level was developed. It was based on the co-encapsulation
of PTX, MNPs and QDs into the hydrophobic core of a self-
assembled Biotin–PEG–PCDA block co-polymer. The NPs were
highly stable under physiological conditions, but were quickly
dis-assembled to release their drug loads in the presence of
10 mM GSH. The NPs were efficiently up-taken by tumour cells
from the combined effect of magnet field guided NP concentration
and biotin receptor-mediated internalization. It can provide efficient
intracellular GSH-triggered release of curcumin and PTX to offer
simultaneous dual-drug treatment, leading to significantly improved
therapeutic efficacy against multidrug resistant MCF-7/ADR cells.
Taken together, the PTX/MNPs/QDs@Biotin–PEG–PCDA NP
Fig. 7 PTX-dose dependent in vitro cytotoxicity of the diﬀerent PTX formula-
tions against the drug resistant MCF-7/ADR cells after 48 h incubation.
Table 2 IC50 values and the drug resistance reversion index (RRI) of
various formulations of PTX against MCF-7/ADR cells
Formulations IC50 values (mg mL
1) RRIa
Free PTX 14.9 —
Free PTX + curcumin 9.4 1.6
PTX@PEG–PCDA 7.1 2.1
PTX@BPP 1.68 8.9
PTX/MNPs/QDs@BPP 1.70 8.7
PTX/MNPs/QDs@BPP
Plus magnetic field 0.89 16.7
a Resistance reversion index (RRI): the ratio of IC50 for free paclitaxel to
that of paclitaxel with reversal agents against the MCF-7/ADR cells.
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which combines the ability of fluorescence tracking, MNP/
biotin based dual-modal targeting and efficient cell uptake,
GSH-triggered intracellular dual-drug release and simultaneous
synergistic dual-drug treatment appears to be a novel and
effective multifunctional nanomedicine for overcoming MDR
in cancer cells. Further work will be focused on exploiting this
multifunctional NP for in vivo applications.
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